[go: up one dir, main page]

FI3442538T3 - Levodopan aiheuttaman dyskinesian hoito trapidiililla - Google Patents

Levodopan aiheuttaman dyskinesian hoito trapidiililla

Info

Publication number
FI3442538T3
FI3442538T3 FIEP17779608.3T FI17779608T FI3442538T3 FI 3442538 T3 FI3442538 T3 FI 3442538T3 FI 17779608 T FI17779608 T FI 17779608T FI 3442538 T3 FI3442538 T3 FI 3442538T3
Authority
FI
Finland
Prior art keywords
trapidil
deuterated
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
FIEP17779608.3T
Other languages
English (en)
Inventor
Aarash Bordbar
Original Assignee
Sinopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinopia Biosciences Inc filed Critical Sinopia Biosciences Inc
Application granted granted Critical
Publication of FI3442538T3 publication Critical patent/FI3442538T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catching Or Destruction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (13)

PATENTTIVAATIMUKSET
1. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi levodopan aiheuttaman dyskinesian hoidossa tai ehkäisyssä subjektissa.
2 Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi patenttivaatimuksen 1 mukaisesti, jolloin subjekti on ihminen.
3. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi patenttivaatimuksen 1 tai patenttivaatimuksen 2 mukaisesti, jolloin — trapidiilin tai deuteroidun trapidiilin farmaseuttisesti hyväksyttävä suola käsittää suolan suolahapon, bromivetyhapon, jodivetyhapon, rikkihapon, typpihapon, oksaalihapon, malonihapon tai viinihapon kanssa.
4. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola — käytettäväksi jonkin patenttivaatimuksen 1-3 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävää suolaa annetaan levodopan kanssa.
5. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi patenttivaatimuksen 4 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai — sen farmaseuttisesti hyväksyttävä suola ja levodopa on formuloitu erillistä antoa varten.
6. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi patenttivaatimuksen 4 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola annetaan samanaikaisesti levodopan kanssa.
7. — Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi patenttivaatimuksen 4 tai patenttivaatimuksen 5 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola annetaan levodopan antamisen jälkeen.
8. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi patenttivaatimuksen 4 tai patenttivaatimuksen 5 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola annetaan ennen levodopan antoa.
9. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi patenttivaatimuksen 4 tai patenttivaatimuksen 6 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola ja levodopa annetaan yhdistettynä annosmuotona.
10. Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi jonkin patenttivaatimuksen 1-9 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola on formuloitu oraalista antoa varten.
11 Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi jonkin patenttivaatimuksen 4-9 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola ja levodopa on formuloitu oraalista antoa varten.
12 Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi jonkin patenttivaatimuksen 1-9 mukaisesti, jolloin trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola on formuloitu parenteraalista antoa varten.
13 Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi jonkin patenttivaatimuksen 4-9 mukaisesti, jolloin Trapidiili, deuteroitu trapidiili tai sen farmaseuttisesti hyväksyttävä suola ja levodopa on formuloitu parenteraalista antoa varten.
FIEP17779608.3T 2016-04-04 2017-04-03 Levodopan aiheuttaman dyskinesian hoito trapidiililla FI3442538T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317983P 2016-04-04 2016-04-04
PCT/US2017/025788 WO2017176652A2 (en) 2016-04-04 2017-04-03 Treating extrapyramidal syndrome using trapidil

Publications (1)

Publication Number Publication Date
FI3442538T3 true FI3442538T3 (fi) 2025-09-04

Family

ID=60001402

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17779608.3T FI3442538T3 (fi) 2016-04-04 2017-04-03 Levodopan aiheuttaman dyskinesian hoito trapidiililla

Country Status (10)

Country Link
US (3) US10350212B2 (fi)
EP (1) EP3442538B1 (fi)
JP (3) JP7049683B2 (fi)
CN (2) CN109310700A (fi)
AU (1) AU2017246334C1 (fi)
CA (1) CA3054674A1 (fi)
DK (1) DK3442538T3 (fi)
ES (1) ES3039958T3 (fi)
FI (1) FI3442538T3 (fi)
WO (1) WO2017176652A2 (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310700A (zh) * 2016-04-04 2019-02-05 希诺皮亚生物科学公司 使用曲匹地尔治疗锥体外系综合征
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
CA3163242A1 (en) * 2019-12-02 2021-06-10 Aarash BORDBAR Treating cognitive disorders using trapidil
JP7730336B2 (ja) * 2020-03-26 2025-08-27 シノピア バイオサイエンシーズ，インク． 同位体標識トラピジル誘導体
WO2024053728A1 (ja) * 2022-09-09 2024-03-14 住友ファーマ株式会社 対象の状態の予測およびその応用
CN116754348B (zh) * 2023-06-06 2024-03-08 华北理工大学 基于zif-8-90材料的泡腾片、其制备方法及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
EP0773227A1 (en) 1991-09-18 1997-05-14 Affymax Technologies N.V. Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
EP0916396B1 (en) 1991-11-22 2005-04-13 Affymetrix, Inc. (a Delaware Corporation) Combinatorial strategies for polymer synthesis
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) * 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
EP1646377A4 (en) * 2003-07-11 2009-09-09 Merck & Co Inc TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
EP1732544A2 (en) * 2004-03-26 2006-12-20 Merck & Co., Inc. Treatment of tremor with histamine h3 inverse agonists or histamine h3 antagonists
EP3730507A1 (en) * 2005-11-18 2020-10-28 Cornell Research Foundation, Inc. Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US9084820B2 (en) 2008-04-18 2015-07-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Magnetic microstructures for magnetic resonance imaging
BR112013016708B1 (pt) 2010-12-30 2021-08-17 Foundation Medicine, Inc Otimização de análise multigene de amostras de tumor
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
WO2017059118A1 (en) * 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
WO2017117240A1 (en) 2015-12-29 2017-07-06 JONES AND MALTERER TECHNOLOGY INNOVATIONS INCORPORATED, d/b/a JAMTek Multi-point synchronizable and scalable lighting control systems
CN109310700A (zh) 2016-04-04 2019-02-05 希诺皮亚生物科学公司 使用曲匹地尔治疗锥体外系综合征
JP7730336B2 (ja) 2020-03-26 2025-08-27 シノピア バイオサイエンシーズ，インク． 同位体標識トラピジル誘導体

Also Published As

Publication number Publication date
US11628170B2 (en) 2023-04-18
US20230201205A1 (en) 2023-06-29
EP3442538A2 (en) 2019-02-20
ES3039958T3 (en) 2025-10-27
EP3442538B1 (en) 2025-07-23
EP3442538A4 (en) 2019-11-20
WO2017176652A2 (en) 2017-10-12
CN109310700A (zh) 2019-02-05
CA3054674A1 (en) 2017-12-10
CN116509869A (zh) 2023-08-01
AU2017246334A1 (en) 2018-11-15
AU2017246334C1 (en) 2022-11-17
WO2017176652A3 (en) 2018-05-17
DK3442538T3 (da) 2025-09-01
JP2022088469A (ja) 2022-06-14
US20190328741A1 (en) 2019-10-31
JP2024095682A (ja) 2024-07-10
JP7049683B2 (ja) 2022-04-07
US10350212B2 (en) 2019-07-16
AU2017246334B2 (en) 2022-07-28
JP2019510826A (ja) 2019-04-18
US20180243307A1 (en) 2018-08-30
US12268691B2 (en) 2025-04-08

Similar Documents

Publication Publication Date Title
FI3442538T3 (fi) Levodopan aiheuttaman dyskinesian hoito trapidiililla
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
MX2021002322A (es) Nuevos metodos.
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
JP2016518337A5 (fi)
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
JP2016147915A5 (fi)
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
FI4212152T3 (fi) Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
MX2016006318A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
HRP20241552T1 (hr) Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost
JP2019510826A5 (fi)
BR112014025737A2 (pt) método para administrar um agente terapêutico, método para prevenir a entrada de um agente terapêutico, método para modular a velocidade de liberação de um agente terapêutico, agente terapêutico, formas de dosagem, método de tratamento de uma doença e kit de partes
FI3044229T3 (fi) Peptidejä käytettäväksi suun limakalvotulehduksen hoidossa
WO2015079010A3 (en) Pharmaceutical composition comprising lacosamide and levetiracetam
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
WO2015107536A3 (en) Fixed dose combination comprising linagliptin and metformin hci
PH12020500032A1 (en) Isotretinoin oral-mucosal fromulations and methods for using same
EP4470611A3 (en) Levodopa and carbidopa intestinal gel and methods of use
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
UA117243C2 (uk) Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії